In this Healio video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, highlights recent coverage examining the persistence of difficult-to-treat immune-mediated inflammatory disease in the biologic era.“I think we’re taking a more holistic and realistic approach to these patients,” Calabrese said. “And we have some world experts weighing in on several high-impact publications just within the past 6 months.”Calabrese additionally discussed coverage from the Rheumatology Nurses Society Annual Conference regarding integrative
September 22, 2026
1 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Added to email alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, highlights recent coverage examining the persistence of difficult-to-treat immune-mediated inflammatory disease in the biologic era.
“I think we’re taking a more holistic and realistic approach to these patients,” Calabrese said. “And we have some world experts weighing in on several high-impact publications just within the past 6 months.”
Calabrese additionally discussed coverage from the Rheumatology Nurses Society Annual Conference regarding integrative medicine, particularly the use of herbs and supplements alongside traditional medicine.
“We also have some great coverage from RNS on integrative immunology, and the role of chamomile, perhaps, in improving quality of life,” he said.
For more information:Leonard H. Calabrese, DO, can be reached at calabrl@ccf.org or at rheumatology@healio.com.
Published by:
Healio Interview
Disclosures: Calabrese reports being a medical advisor for OpenEvidence, as well as professional relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB.
Ask a clinical question and tap into Healio AI's knowledge base.
Read more about
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Added to email alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | A new era for difficult immune-mediated inflammatory diseases | 0 | 11.06 | 21-09-2026 |
| 2 | ‘Pain is a real disease’: Treating chronic pain requires multidisciplinary approach | 0 | 8.18 | 24-09-2026 |
| 3 | Hooked on Rheum with Brittany Hill, DO | 0 | 8.14 | 16-09-2026 |
| 4 | ‘Think critically’: Caution key in assessing clinical trial data | 0 | 7.73 | 19-09-2026 |
| 5 | Speaker: CAR T-cell trial deaths add ‘sobriety’ to discussions with autoimmune patients | 0 | 9.17 | 28-09-2026 |
| 6 | Speaker: GLP-1s may be anti-inflammatory ‘even without obesity’ | 0 | 10.61 | 20-09-2026 |
| 7 | SetPoint System ‘increasing its effectiveness over time’ in RA | 0 | 7.81 | 18-09-2026 |
| 8 | FDA fast tracks Yutrepia for Raynaud’s phenomenon in SSc | 0 | 8.46 | 17-09-2026 |
| 9 | Newly discovered inflammatory cell signaling could open the door to autoimmune disease treatments | 0 | 10.81 | 23-09-2026 |
| 10 | Ученые связали трудноизлечимый артрит с депрессией и нарушениями сна | 0 | 7.53 | 28-09-2026 |